Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Revenue (2017 - 2026)

Neurocrine Biosciences filings provide 15 years of Revenue readings, the most recent being $805.5 million for Q4 2025.

  • On a quarterly basis, Revenue rose 28.33% to $805.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.9 billion, a 21.45% increase, with the full-year FY2025 number at $2.9 billion, up 21.45% from a year prior.
  • Revenue hit $805.5 million in Q4 2025 for Neurocrine Biosciences, up from $794.9 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $805.5 million in Q4 2025 to a low of $20.0 million in Q2 2022.
  • Median Revenue over the past 5 years was $475.8 million (2023), compared with a mean of $468.3 million.
  • Biggest five-year swings in Revenue: plummeted 93.08% in 2022 and later soared 2163.5% in 2023.
  • Neurocrine Biosciences' Revenue stood at $312.0 million in 2021, then surged by 32.05% to $412.0 million in 2022, then grew by 25.05% to $515.2 million in 2023, then grew by 21.84% to $627.7 million in 2024, then increased by 28.33% to $805.5 million in 2025.
  • The last three reported values for Revenue were $805.5 million (Q4 2025), $794.9 million (Q3 2025), and $687.5 million (Q2 2025) per Business Quant data.